Astorg Acquires Thermo Fisher Microbiology Business

Astorg has finalized its acquisition of Thermo Fisher Scientific's microbiology diagnostics division, establishing a standalone global entity focused on this critical healthcare segment. This strategic move carves out a significant business unit, positioning it as an independent leader in providing diagnostic solutions for clinical, food safety, and pharmaceutical applications.

The newly independent company, which will soon unveil its distinct brand identity, boasts a robust operational footprint. It serves over 15,000 clients across more than 100 nations and employs approximately 2,400 professionals spread across 13 global research and manufacturing facilities. This extensive reach underscores its established presence in the international diagnostics market.

This transaction aligns perfectly with Astorg's dedicated strategy within the healthcare sector, emphasizing its proficiency in navigating complex deals. The firm's approach combines profound industry knowledge with a proven ability to drive operational enhancements, a hallmark of its investment philosophy. The appointment of Dirk Bontridder as Chief Executive Officer signals a clear intent to propel the company into its next growth phase, supported by Astorg's partnership.

Dirk Bontridder brings over 25 years of extensive leadership experience from the life sciences, diagnostics, and industrial technology sectors. His prior roles include leading PerkinElmer's transformation and serving as CEO of Reynaers Group, alongside significant positions at Eurofins Scientific. His background as a management consultant at McKinsey & Company further bolsters his strategic acumen for this new venture.

The global microbiology diagnostics market is a vital component of the broader in-vitro diagnostics (IVD) industry, which is projected to reach over $100 billion by 2027, driven by increasing demand for rapid and accurate disease detection, stringent food safety regulations, and pharmaceutical quality control. The carve-out of this business by Astorg suggests a belief in its potential for accelerated growth as a focused, independent entity, free from the broader strategic priorities of a large conglomerate.

Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, highlighted the firm's distinctive capability in such intricate transactions. She stated, “This is precisely the type of complex opportunity where Astorg can make a difference, combining deep healthcare expertise, an entrepreneurial and hands-on partnership model, and a strong track record of value creation across the companies we back.” Olivier Lieven, Partner at Astorg, added, “We are delighted to welcome Dirk and look forward to working with him and the management team to deliver the company’s next phase of growth, accelerate innovation and strengthen its global position.”